Subtopic Deep Dive

PTX3 as Cardiovascular Biomarker
Research Guide

What is PTX3 as Cardiovascular Biomarker?

PTX3 serves as a prognostic biomarker for cardiovascular diseases including atherosclerosis, vascular inflammation, unstable angina pectoris, and heart failure due to its specific association with endothelial dysfunction and plaque instability.

PTX3, a long pentraxin produced locally by myeloid and stromal cells, outperforms CRP in detecting acute vascular inflammation (Inoue et al., 2006, 235 citations). Studies show elevated PTX3 plasma levels in unstable angina pectoris patients, enabling early risk stratification (Inoue et al., 2006). Over 10 key papers since 2006 link PTX3 to cardiovascular outcomes, with foundational work establishing sensitive assays (Inoue et al., 2006).

Curated Papers

Key Challenges

Why It Matters

PTX3 enables precise risk stratification in acute myocardial infarction and unstable angina, surpassing CRP by reflecting local inflammation (Inoue et al., 2006; Ristagno et al., 2019). In atherosclerosis, PTX3 correlates with plaque instability and progression, guiding therapies in carotid disease patients (Ammirati et al., 2015). Clinical trials use PTX3 for monitoring essential thrombocythemia thrombosis risks, improving outcomes over generic markers (Barbui et al., 2010).

Key Research Challenges

Assay Sensitivity Limits

Early PTX3 assays lacked precision for low-level detection in stable patients, hindering routine use (Inoue et al., 2006). Developing high-sensitivity plasma tests remains critical for unstable angina diagnosis. Variability in PTX3 production by cell types complicates standardization.

Distinguishing PTX3 from CRP

PTX3 shows superior specificity to CRP in vascular inflammation, but overlapping roles in thrombosis confuse interpretations (Barbui et al., 2010). Studies must isolate PTX3's independent prognostic value in atherosclerosis. Comparative biomarker trials reveal inconsistent elevations.

Plaque Stability Correlation

Linking PTX3 levels to plaque instability requires longitudinal imaging studies beyond cross-sectional data (Ammirati et al., 2015). Prognostic models integrating PTX3 with endothelial markers face validation gaps. COVID-19 data suggest macrophage-driven PTX3 surges, but cardiovascular specificity needs clarification (Brunetta et al., 2020).

Essential Papers

Diagnostic markers of acute myocardial infarction

Mythili Sabesan, Malathi Narasimhan · 2015 · Biomedical Reports · 253 citations

Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide. The highest risk of fatality occurs within the initial hours of onset of AMI. Thus, early diagnosis of cardi...

Establishment of a High Sensitivity Plasma Assay for Human Pentraxin3 as a Marker for Unstable Angina Pectoris

Kenji Inoue, Akira Sugiyama, Patrick Reid et al. · 2006 · Arteriosclerosis Thrombosis and Vascular Biology · 235 citations

Objective— Plasma pentraxin 3 (PTX3) levels are increased in patients with acute myocardial infarction, yet its involvement in unstable angina pectoris (UAP) remains unclear. To critically evaluate...

Evolution of C-Reactive Protein

Asmita Pathak, Alok Agrawal · 2019 · Frontiers in Immunology · 232 citations

C-reactive protein (CRP) is an evolutionarily conserved protein. From arthropods to humans, CRP has been found in every organism where the presence of CRP has been sought. Human CRP is a pentamer m...

PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer

Cecília Garlanda, Barbara Bottazzi, Elena Magrini et al. · 2018 · Physiological Reviews · 196 citations

Innate immunity includes a cellular and a humoral arm. PTX3 is a fluid-phase pattern recognition molecule conserved in evolution which acts as a key component of humoral innate immunity in infectio...

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3

Tiziano Barbui, Alessandra Carobbio, Guido Finazzi et al. · 2010 · Haematologica · 188 citations

We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in patients with essential thrombocythemi...

Markers of Inflammation Associated with Plaque Progression and Instability in Patients with Carotid Atherosclerosis

Enrico Ammirati, Francesco Moroni, Giuseppe Danilo Norata et al. · 2015 · Mediators of Inflammation · 186 citations

Atherosclerosis is the focal expression of a systemic disease affecting medium‐ and large‐sized arteries, in which traditional cardiovascular risk factor and immune factors play a key role. It is w...

Inflammatory Biomarkers and Atherosclerosis

Takeshi Soeki, Masataka Sata · 2016 · International Heart Journal · 175 citations

Atherosclerosis has been regarded as a form of chronic vascular inflammation. Numerous biomarkers associated with inflammation have been identified as novel targets to monitor atherosclerosis and c...

Reading Guide

Foundational Papers

Start with Inoue et al. (2006, 235 citations) for PTX3 assay in unstable angina, then Barbui et al. (2010, 188 citations) for thrombosis comparisons, and Deban et al. (2010, 159 citations) for innate immunity basics.

Recent Advances

Study Ristagno et al. (2019, 163 citations) for PTX3 in CVD overview, Ammirati et al. (2015, 186 citations) for plaque markers, and Brunetta et al. (2020) for macrophage insights.

Core Methods

Core techniques include high-sensitivity plasma ELISA (Inoue et al., 2006), immunohistochemical plaque analysis (Ammirati et al., 2015), and comparative pentraxin profiling vs. CRP (Barbui et al., 2010).

How PapersFlow Helps You Research PTX3 as Cardiovascular Biomarker

Discover & Search

Research Agent uses searchPapers and exaSearch to find PTX3 cardiovascular papers like Inoue et al. (2006), then citationGraph reveals 235-citation impact and connections to Ristagno et al. (2019). findSimilarPapers expands to atherosclerosis biomarkers from 250M+ OpenAlex papers.

Analyze & Verify

Analysis Agent applies readPaperContent to extract PTX3 assay methods from Inoue et al. (2006), verifies claims via CoVe against Garlanda et al. (2018), and uses runPythonAnalysis for meta-analysis of PTX3 vs. CRP levels with GRADE scoring for evidence strength in prognostic studies.

Synthesize & Write

Synthesis Agent detects gaps in PTX3 plaque stability data via contradiction flagging across Ammirati et al. (2015) and Soeki et al. (2016); Writing Agent employs latexEditText, latexSyncCitations for Inoue et al. (2006), and latexCompile for biomarker comparison tables with exportMermaid diagrams.

Use Cases

"Meta-analyze PTX3 levels vs CRP in unstable angina cohort studies"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of levels from Inoue et al. 2006 and Barbui et al. 2010) → statistical p-values and GRADE scores output.

"Draft review section on PTX3 in atherosclerosis with citations"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Ammirati et al. 2015, Soeki et al. 2016) → latexCompile → formatted LaTeX section with figure.

"Find code for PTX3 ELISA assay analysis from papers"

Research Agent → paperExtractUrls (Inoue et al. 2006) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R script for sensitivity curve plotting.

Automated Workflows

Deep Research workflow scans 50+ PTX3 papers via searchPapers → citationGraph → structured report on cardiovascular prognostic value with Inoue et al. (2006) centrality. DeepScan applies 7-step CoVe to verify PTX3 superiority over CRP in Ammirati et al. (2015). Theorizer generates hypotheses on PTX3-macrophage interactions from Brunetta et al. (2020) and Garlanda et al. (2018).

Try Doxa for PTX3 as Cardiovascular Biomarker Research

Frequently Asked Questions

What defines PTX3 as a cardiovascular biomarker?

PTX3 is a long pentraxin elevated in unstable angina and atherosclerosis, produced locally by inflamed tissues unlike systemic CRP (Inoue et al., 2006; Ristagno et al., 2019).

What methods measure PTX3 in plasma?

High-sensitivity ELISA assays detect PTX3 at pg/mL levels, validated for unstable angina prognosis (Inoue et al., 2006).

What are key papers on PTX3 in CVD?

Inoue et al. (2006, 235 citations) established PTX3 assays for UAP; Ristagno et al. (2019) reviewed PTX3 in heart disease; Garlanda et al. (2018, 196 citations) detailed innate immunity roles.

What open problems exist for PTX3 research?

Validating PTX3 for plaque stability prediction needs prospective trials; standardizing assays across cohorts persists (Ammirati et al., 2015); distinguishing vascular from systemic inflammation requires integrated models.